Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation

DISEASE CHARACTERISTICS: * Diagnosis of post-transplant lymphoproliferative disease (PTLD) after solid organ (heart, heart/lung, liver, liver/gut, pancreas, or kidney) transplantation * Epstein-Barr virus-positive tumor * Newly diagnosed disease * Measurable disease by clinical methods or radiography * Must have partially matched donor cytotoxic T cells (CTL) available * No known panel reactivity to any of the HLA types of CTL available for therapy PATIENT CHARACTERISTICS: Age: * Any age Performance status: * Karnofsky 20-100% Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Other: * Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Not specified Endocrine therapy: * Not specified Radiotherapy: * Not specified Surgery: * Not specified Other: * No prior therapy for PTLD * No concurrent antiviral drugs (e.g., acyclovir or ganciclovir) for PTLD